NCT04526288View on ClinicalTrials.gov

CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

August 9, 2021

Primary Completion Date

August 27, 2023

Study Completion Date

August 27, 2023

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndrome With Excess Blasts-2Myeloid Neoplasm
Interventions
PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo alloHCT

DRUG

Liposome-encapsulated Daunorubicin-Cytarabine

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Jazz Pharmaceuticals
All Listed Sponsors
collaborator

Jazz Pharmaceuticals

INDUSTRY

lead

Fred Hutchinson Cancer Center

OTHER